BRAF and melanoma: We repeated this specific analysis in a validation cohort of patients diagnosed with cutaneous stage III melanoma treated with adjuvant anti‐PD1; log‐rank analysis showed no statistical difference; however, regression analysis accounting for the significant difference in age between groups showed BRAF V600 mutation to be associated with an increased hazard for recurrence.